Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1/2 inhibitor ruxolitinib by Goldsmith, Scott R. et al.
Washington University School of Medicine 
Digital Commons@Becker 
Open Access Publications 
2019 
Resolution of secondary hemophagocytic lymphohistiocytosis 
after treatment with the JAK1/2 inhibitor ruxolitinib 
Scott R. Goldsmith 
Sana Saif Ur Rehman 
Cara L. Shirai 
Kiran Vij 
John F. DiPersio 
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs 
EXCEPTIONAL CASE REPORT
Resolution of secondary hemophagocytic lymphohistiocytosis after
treatment with the JAK1/2 inhibitor ruxolitinib
Scott R. Goldsmith,1,2 Sana Saif Ur Rehman,2 Cara L. Shirai,3 Kiran Vij,1,3 and John F. DiPersio1
1Division of Oncology, Department of Medicine, 2Division of Hematology, Department of Medicine, and 3Department of Pathology and Immunology, Washington University
School of Medicine, St. Louis, MO
Key Points






with a ruxolitinib taper





Secondary hemophagocytic lymphohistiocytosis (HLH) is an acquired syndrome of immune dysregulation.1-3
Depending on the severity of manifestations, therapy ranges from observation alone to combinations of
corticosteroids, etoposide, and/or cyclosporine, based on treatment data in familial HLH.4,5 Notably,
there is a paucity of data on salvage therapies.6-8
Key inflammatory cytokines that propagate HLH bind to receptors that signal via the JAKs, which
phosphorylate the STAT transcription factors.9,10 The JAK/STAT cascade promotes expression of
genes that further expand the hyperinflammatory state.
Das et al11 developed a murine model of secondary HLH in which repeated cytosine guanine
dinucleotide DNA injection into wild-type B6 mice triggered the innate immune response via
Toll-like receptor 9. Subsequent inhibition of JAK1/2 via ruxolitinib led to resolution of spleno-
megaly and cytopenias, reduction of inflammatory cytokines, and attenuation of pathologic T-cell
expansion. Maschalidi et al12 observed such findings in perforin knockout mice. Using these
same models, Albeituni et al13 showed the superiority of ruxolitinib over interferon-g inhibition
(the target of emapalumab-lzsg), providing broader immune normalization and improving symptoms
and survival.
Here we describe 2 consecutive cases in which ruxolitinib was used as salvage therapy for refractory
secondary HLH. Ruxolitinib resulted in rapid and complete resolution of clinical manifestations, obviating
the need for further intensive chemotherapy or allogeneic stem cell transplantation.
Case descriptions, methods, and results
Case 1
A 24-year-old woman presented to an outside hospital with nausea, myalgias, and jaundice. She had a
new anemia with a hemoglobin level of 9 g/dL, an indirect hyperbilirubinemia (total bilirubin, 11.5 mg/dL),
an undetectable haptoglobin, and detection of an anti-IgG warm autoantibody, concerning for an
autoimmune hemolytic anemia. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome
were excluded because the patient’s blood smear lacked schistocytes and renal function was
unaffected. She started prednisone at 100 mg daily. Her subsequent hemoglobin level fell to 4.7 g/dL,
prompting administration of 1 g of methylprednisolone. Despite transfusion of 8 U of blood
over 48 hours, her hemoglobin level continued to downtrend to 3.1 g/dL, with a total bilirubin level of
17 mg/dL and lactate dehydrogenase level of 1016 U. She was given intravenous immunoglobulin and
transferred to our institution.
Shortly after arrival, the patient developed a fever to 38.9°C, somnolence, had palpable splenomegaly,
and remained profoundly anemic with a hemoglobin nadir of 2.8 g/dL despite transfusion of 21 U.
Rituximab was added for refractory autoimmune hemolytic anemia. Surprisingly, she had a low
reticulocyte percentage of 0.4%, hyperferritinemia to 58 505 ng/mL, and hypertriglyceridemia to
269 mg/dL. Her platelets also declined from 276 3 109/L to 843 109/L shortly after transfer. Results of
a bone marrow biopsy revealed abundant hemophagocytosis with no evidence of malignancy; results of
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a skin biopsy were negative for intravascular lymphoma, and com-
puted tomography scans were negative for mass or lymphadenopathy.
Although the patient’s presentation started with autoimmune
hemolytic anemia, she had progressed to meeting HLH criteria with
an HScore of 228 (Table 1).14,15 Infectious etiologies were ruled out,
and rheumatologic evaluation suggested juvenile idiopathic arthritis
with resultant macrophage activation syndrome and HLH.16 A
molecular panel for familial HLH mutations was negative. The patient
began developing liver and renal failure, with direct hyperbilirubinemia
and coagulopathy. Given her multiorgan-system failure, splenectomy
was considered too risky, especially because it would address only
the hemolysis and not the HLH; the HLH-94 protocol was therefore
initiated. However, the patient had persistent high fevers and
transfusion-refractory hemolytic anemia with hypoproliferative hema-
topoiesis from HLH. She continued to deteriorate with cardiac
ischemia and progressive hepatic failure, with total and direct bilirubin
levels subsequently peaking at 95.2 and 82.0 mg/dL, respectively.
Out of concern that the patient had developed refractory HLH, it was
planned that she receive alemtuzumab as a final and unproven
salvage therapy, although it was not immediately available. Based on
the preclinical data on JAK/STAT inhibition in HLH models, and in the
prevention and treatment of graft-versus-host disease in both mouse
models and humans, we initiated treatment with ruxolitinib at a dose
of 5 mg twice daily, without altering her steroid dose.17-20 Within
48 hours, her bilirubin, lactate dehydrogenase, and ferritin trends
significantly improved, her fevers resolved, and she became responsive
to blood transfusions (Figure 1A-B). Despite these improvements,
alemtuzumab was administered 2 days later because of the severity
of the initial disease and elevated, albeit improving, ferritin.
After about 2 weeks, the patient’s ruxolitinib dose was increased to
20 mg twice daily due to an acutely worsening anemia with
concomitant up-trending ferritin and C-reactive protein levels; she
remained afebrile, however, requiring only prophylactic antimicrobial
agents. She experienced mild fatigue and arthralgias during her
treatment course, but severe treatment-related toxicities were not
observed, even at peak hepatic dysfunction. The patient has been
successfully tapered off ruxolitinib after 3 months of therapy, with no
recurrence of HLH manifestations.
Case 2
A 26-year-old woman had presented to a local hospital with severe
myalgias and fevers up to 39.5°C. She was diagnosed with both
acute hepatitis C virus and Epstein-Barr virus (EBV) infections, with
initial viral loads of 57000 and 23000 copies/mL, respectively. She
underwent an abdominal ultrasound, which revealed splenomegaly
without hepatomegaly or cirrhosis.
The patient’s ferritin level on admission was 24 023 ng/mL and her
triglyceride level was 369 mg/dL, which, along with splenomegaly
and persistent fevers, prompted a bone marrow biopsy; the results
of the biopsy revealed hemophagocytosis without malignancy.
Despite initial treatment with corticosteroids, the patient developed
encephalopathy. Atypical lymphocytes (absolute count, 64) among
Table 1. Clinical and laboratory manifestations of HLH in presented cases as classified according to HLH-2004 diagnostic criteria and the
HScore
Classification Case 1 Case 2
HLH-2004 diagnostic criteria5
Fevers Yes (Tmax 38.9°C) Yes (Tmax 39.5°C at first hospital)
Splenomegaly Yes Yes
Peripheral blood cytopenias (.2 lineages)* Yes (platelet nadir 843 109/L, hemoglobin nadir 2.8 g/dL) Yes (platelet nadir 853 109/L, hemoglobin nadir 8.5 g/dL)
Hypertriglyceridemia (.265 mg/dL) Yes (269 mg/dL) Yes (369 mg/dL)
Hemophagocytosis Yes Yes
Hyperferritinemia Yes (58 505 ng/mL) Yes (24919 ng/mL)
Low/absent NK cell activity No No
Elevated soluble CD25 Not assessed Not assessed
HLH-associated mutations No No
HScore14,15
Known immunosuppression No (10 pts) No (10 pts)
Temperature 38.4-39.4 (133 pts) .39.4 (149 pts)
Organomegaly Splenomegaly (123 pts) Splenomegaly (123 pts)
Lineages of cytopenias† 2 (124 pts) 2 (124 pts)
Ferritin, ng/mL .6000 (150 pts) .6000 (150 pts)
Triglyceride, mg/dL 132.7-354 (144 pts) .354 (164 pts)
Fibrinogen, mg/dL .250 (10 pts) .250 (10 pts)
AST $30 (119 pts) $30 (119 pts)
Hemophagocytosis on bone marrow Yes (135 pts) Yes (135 pts)
Total HScore 228 (96%-98% probability of HLH) 264 (.99% probability of HLH)
AST, aspartate aminotransferase; NK, natural killer; pts, points; Tmax, maximum temperature.
*Cytopenias defined as hemoglobin ,9 g/dL, platelets ,1003 109/L, and absolute neutrophil count ,1 3 109/L.
†Cytopenias defined as #9.2 g/dL, white blood cell count #5 3 109/L, and platelets #1103 109/L.
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erythrocytes were noted in the cerebrospinal fluid, although they
were negative for malignancy according to flow cytometry. No
pathogen was identified in the cerebrospinal fluid, and results of
a brain MRI were unremarkable. The patient acutely decompen-
sated with rapid development of anemia (hemoglobin, 8.5 g/dL),
thrombocytopenia (platelet count, 853 109/L), and respiratory
arrest. She met HLH criteria (Table 1) with an HScore of 264;
treatment on the HLH-94 protocol with intrathecal methotrexate
was therefore initiated and continued for 8 weeks. Her ferritin level
declined to a nadir of 786 ng/mL, and her cerebrospinal fluid
cleared. Mutational testing for familial HLH was negative, perforin
was normal, and granzyme B levels were elevated in natural killer
cells; CD107a flow cytometry was inconclusive.
Shortly after cessation of therapy, the patient developed recurrent
fevers, hypotension, and encephalopathy with hyperferritinemia to
24 919 ng/mL, concerning for treatment-refractory HLH, although
results of a repeat EBV DNA polymerase chain reaction were
negative. This prompted a transfer to our center for management
and transplant evaluation.
Results of a repeat bone marrow biopsy for the patient revealed
abundant hemophagocytosis, and her ferritin level was 15073 ng/mL.
We initiated salvage treatment with ruxolitinib at a dose of 10 mg
twice daily. The patient’s fevers and encephalopathy quickly
abated, with the ferritin levels falling to 2973 ng/mL within 3 days
(Figure 1C-D). Her blood counts recovered, and her transaminase
levels normalized. A small subsequent elevation in her ferritin level
prompted an increase of the ruxolitinib dose to 20mg twice daily. Her
hospital course remained uncomplicated thereafter, and she was
discharged on ruxolitinib maintenance at 20 mg twice daily. Although
the patient’s ferritin level remained elevated around 1000 ng/mL
shortly after discharge, it normalized over successive months. On
ruxolitinib, the patient was initially mildly bicytopenic (hemoglobin,
8.6-10.3 g/dL; platelet counts, 125-3113 109/L), which resolved as
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Figure 1. Effect of ruxolitinib on laboratory parameters (to last follow-up) and fevers (during hospitalization) with time course of therapy administration in
the treatment of relapsed/refractory secondary HLH. Patient 1 (A-B) and patient 2 (C-D). CRP, C-reactive protein; Tmax, maximum temperature.
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remains undetectable, along with her hepatitis C virus viral load as
she completed therapy with glecaprevir/pibrentasvir.
Discussion
These 2 cases illustrate the potential role of ruxolitinib as salvage
therapy for refractory HLH exhibiting a rapid and durable clinical
benefit. To date, one of the patients has been tapered off of
ruxolitinib without recurrence, and the other is being weaned
successfully.
Front-line ruxolitinib use has been reported in 2 elderly patients with
HLH associated with sepsis.21,22 As salvage therapy, it has been
successfully used as a bridge to allogeneic transplant in 2 pediatric
cases of refractory HLH associated with inherited mutations.23,24
One report describes its use as salvage therapy in an adult, resulting
in an improvement in inflammatory markers, although the patient died
7 days after initiation of ruxolitinib.25
Our analysis is the first to describe the successful treatment of
refractory HLH with ruxolitinib in adults, with use as maintenance
therapy to circumvent the need for allogeneic stem cell trans-
plantation. We have yet to treat other cases of HLH with ruxolitinib
at our institution but regard it as an attractive and effective
alternative to other tried and unproven salvage therapies in patients
with relapsed/refractory HLH. Although early-phase, single-arm
trials incorporating ruxolitinib are ongoing (NCT02400463,
NCT03795909, and NCT03533790), the relative benefit of
ruxolitinib compared with HLH-94 and other HLH therapies
would best be tested in future randomized clinical trials.
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